Vericel CORP

Market Movers (8-K)

See all →
NASDAQ
Vericel Corporation reported a strong third quarter of 2026 with 26% revenue growth to $85.4 million and a 179% increase in net income to $14.2 million, leading to raised full-year financial guidance.
Better than expected
NASDAQ
Vericel Corporation announced robust second quarter 2026 financial results, exceeding expectations with a 22% revenue increase and raising full-year guidance, alongside a new $200 million share repurchase program.
Better than expected
NASDAQ
Vericel Corporation has updated its bylaws to reflect its relocation to a new global headquarters in Burlington, Massachusetts.
NASDAQ
Vericel Corporation announced robust first quarter 2026 financial results, with total revenue up 30% to $68.4 million, and raised its full-year revenue guidance.
Better than expected
NASDAQ
Vericel Corporation reported robust financial results for the fourth quarter and full-year 2025, driven by significant revenue and profit growth across its advanced therapies.
Better than expected
NASDAQ
Vericel Corporation announced preliminary, unaudited financial results for fiscal year 2025, projecting strong revenue growth and profitability, driven by record MACI performance.
Better than expected

Quarterly Earnings (10-Q)

See all →
NASDAQ
Vericel Corporation's Q3 2026 results show a significant increase in revenue and net income, driven by strong performance across its product portfolio.
Better than expected
NASDAQ
Vericel Corporation announced a significant increase in total revenue for the second quarter of 2026, driven by robust performance in its MACI and Epicel product lines, alongside positive operational cash flow.
NASDAQ
Vericel Corporation announced a 30.1% increase in total revenue for the first quarter of 2026, driven by significant growth in MACI and Epicel sales.
Better than expected
NASDAQ
Vericel Corporation reported a significant turnaround to net income in Q3 2025, driven by robust MACI sales and NexoBrid growth, despite a decline in Epicel revenue.
Delay expected
Better than expected
NASDAQ
Vericel Corporation announced a significant increase in total revenue for the first half of 2025, fueled by strong performance in its MACI and NexoBrid products, though the company's net loss widened due to increased operating expenses.
Worse than expected
NASDAQ
Vericel Corporation's Q1 2025 results show revenue growth driven by MACI and NexoBrid, offset by a decline in Epicel sales, resulting in a net loss of $11.2 million.
Worse than expected

Annual Reports (10-K)

NASDAQ
Vericel Corporation achieved significant revenue and net income growth in 2025, fueled by strong MACI sales and NexoBrid expansion, while advancing its product pipeline.
Better than expected
NASDAQ
Vericel Corporation achieves profitability in 2024, fueled by strong MACI performance and strategic expansion in sports medicine and burn care markets.
Better than expected
NASDAQ
Vericel Corporation's 10-K filing details its 2023 financial performance, product portfolio, and strategic outlook, highlighting growth in MACI sales and the launch of NexoBrid.
Better than expected
Capital raise

Insider Trading (Form 4)

See all →
NASDAQ
Joseph Anthony Mara Jr, Chief Financial Officer of Vericel Corp, sold 25,008 shares of common stock on November 9, 2026.
NASDAQ
Kevin F Mclaughlin, a Director of Vericel Corp, sold 7,000 shares of common stock on November 10, 2026 for $58.96 per share.
NASDAQ
Robert L Zerbe, a Director of Vericel Corp, sold 2,000 shares of common stock on November 9, 2026 for $57.88 per share.
NASDAQ
Joseph Anthony Mara Jr, Chief Financial Officer of Vericel Corp, sold 50,000 shares of common stock on November 5, 2026.
NASDAQ
Kevin F Mclaughlin, a Director of Vericel Corp, sold 7,000 shares of common stock on August 12, 2026 for $44.53 per share.
NASDAQ
Michael Halpin, Chief Operating Officer of Vericel Corp, sold 10,000 shares of common stock on August 3, 2026 for $46.84 per share.

Proxy Statements (Def-14A)

NASDAQ
Vericel Corporation achieved record full-year revenue of $276.3 million in 2025, marking its second consecutive year of GAAP profitability and significant growth across its product portfolio.
Better than expected
NASDAQ
Vericel Corporation announces its 2025 Annual Meeting of Shareholders to be held virtually on April 30, 2025, with several key proposals for shareholder vote.
NASDAQ
Vericel Corporation reports strong financial and business results for 2024, driven by revenue growth and profitability improvements, and anticipates continued growth in 2025.
Better than expected
NASDAQ
Vericel Corporation announces its 2024 Annual Meeting of Shareholders to be held virtually on May 1, 2024, with voting open until April 30, 2024.
NASDAQ
Vericel Corporation announces a strong financial year in 2023, with significant revenue growth and key business milestones, setting the stage for continued success in 2024.
Better than expected
Delay expected

Schedule 13G - Passive Investments

See all →
NASDAQ
Soleus Capital Master Fund, L.P. and associated entities have reported beneficial ownership of 2.8% of Vericel Corp. common stock as of June 30, 2026.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 2,603,128 shares of Vericel Corp common stock, representing 5.11% of the class, as of March 31, 2026.
NASDAQ
Soleus Capital Master Fund and related entities have reported a 5.0% passive beneficial ownership in Vericel Corp's common stock.
NASDAQ
The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Vericel Corp common stock following an internal organizational realignment.
NASDAQ
Brown Capital Management, LLC has filed an amendment to its Schedule 13G, disclosing a 3.87% beneficial ownership in Vericel Corporation's common stock.
NASDAQ
State Street Corporation has reported a 5.6% beneficial ownership stake in Vericel Corp, holding 2,807,242 shares of common stock as of September 30, 2025.